Radiopharm Theranostics
$0.02
5
+$0+0% Tuesday 21:00
Statistics
Day High
0.02
Day Low
0.02
52W High
0.02
52W Low
0.01
Volume
25,000
Avg. Volume
1,229
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
27FebExpected
Expected EPS
-0.007089765668915121
Actual EPS
-0.009845594435075886
Financials
-16,217.19%Profit Margin
Unprofitable199,576.52Revenue
-32.37MNet Income
Analyst Ratings
$16.00Average Price Target
The highest estimate is 16.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow RDPTF. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Show more...
CEO
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD
Country
AU
ISIN
AU0000181851
Listings
0 Comments
Share your thoughts
FAQ
What is Radiopharm Theranostics stock price today?▼
The current price of RDPTF is $0.02 USD — it has increased by +0% in the past 24 hours. Watch Radiopharm Theranostics stock price performance more closely on the chart.
What is Radiopharm Theranostics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Radiopharm Theranostics stocks are traded under the ticker RDPTF.
When is the next Radiopharm Theranostics earnings date?▼
Radiopharm Theranostics is going to release the next earnings report on September 24, 2026.
What were Radiopharm Theranostics earnings last quarter?▼
RDPTF earnings for the last quarter are -0.01 USD per share, whereas the estimation was -0.01 USD resulting in a -38.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Radiopharm Theranostics revenue for the last year?▼
Radiopharm Theranostics revenue for the last year amounts to 199,576.52 USD.
What is Radiopharm Theranostics net income for the last year?▼
RDPTF net income for the last year is -32.37M USD.
When did Radiopharm Theranostics complete a stock split?▼
Radiopharm Theranostics has not had any recent stock splits.
Where is Radiopharm Theranostics headquartered?▼
Radiopharm Theranostics is headquartered in Carlton, AU.